Multiple sclerosis: Long-term remission after a high close of cyclophosphamide

Acta Neurologica Scandinavica

Volumn 111, Issue 3, 2005, Pages 195-198

  De Bittencourt, Paulo R M ^a,b   Gomes Da Silva, M M ^a  

^a Unidade de Neurologia Clinica   (Brazil)

^b NONE   (Brazil)

Author keywords

Bone marrow transplantation; Chemotherapy; Cyclophosphamide; Demyelinating diseases; Demyelination; Immune suppression; Multiple sclerosis; Neuroimmunology; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; GADODIAMIDE; MESNA; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACCIDENT; ADULT; ALOPECIA; ANAMNESIS; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DEMYELINATION; DISEASE ACTIVITY; DRUG MEGADOSE; DYSURIA; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMMUNOLOGY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; PREMATURE OVARIAN FAILURE; REMISSION; STEM CELL TRANSPLANTATION; VOMITING;

CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; REMISSION INDUCTION;

EID: 14044250814     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00340.x     Document Type: Article

References (16)

1. SANDMANN M, GORZ AM, BATISTA RJV, SEIXAS RR, BITTENCOURT PRM. Timectomia e Imunossupressão em Miastenia Gravis: estudo prospective. Arquivos de Neuropsiquiatria 1990;48:44-8.
2. OLIVEIRA TVO, REINHARDT AMG, GRACIA CM, BITTENCOURT PRM. Tratamento imunossupressor na esclerose múltipla. Arquivos de Neuropsiquiatria 1992;50:295-301.
3. BRODSKY RA, PETRI M, JONES RJ. Systemic lupus erythematosus. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin N Am 2002;26:166-73.
4. MANCARDI GL, SACCARDI R, FILIPPI M et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in multiple sclerosis. Neurology 2001;57:62-7.
5. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for M.S. Guidelines for research protocols. Ann Neurol 1983;13:227-31.
6. GIRARD DP, AIMARD G, PELLET H. Therapeutic immunodepressive en neurologie. Presse Med 1967;75:967-9.
7. CHABER BA, ALLEGRA CJ, CALABRESI P, CURT GA. Antineoplastic agents. In: Hardman JG, Molinoff PB, Gilman AG, eds. Goodman & Gilman' pharmacological basis of therapeutics, 9th edn. New York: McGraw-Hill Companies, 1996;1233-99.
8. GOODIN DS, FROHMAN EM JR, GARMANY GP et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78.
9. LA MANTIA L, MILANESE C, MASCOLI N, INCORVAIA B, D'AMICO R, WEISNTOCK-GUTTMAN B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2002; 4:CD 002819.
10. PERINI P, GALLO P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 2003;250:834-8.
11. PASSAS A, KIMISKIDIS VK. Stem cell transplantation for musltiple sclerosis: what is the evidence. Blood Rev 2003;17:233-40.
12. OPENSHAW H, STUVE O, ANTEL R et al. Multiple Sclerosis flares associated with recombinat granulocyte colony-stimulating factor. Neurology 2000;54:2147-50.
13. BRANNAGAN TH, PRADHAN A, HEIMAN-PATTERSON T et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;2:1856-8.
14. MARTIN F, LAUWERYS B, LEFEBVRE C et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-7.
15. COMI G, KAPPOS L, CLANET M et al. Guidelines for autologous blood and stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group of Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000;247:376-82.
16. SAIZ A, BLANCO Y, CARRERAS E et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004;62:282-4.